Fusion Pharmaceuticals Inc. (FUSN)
NASDAQ: FUSN · IEX Real-Time Price · USD
21.40
0.00 (0.00%)
At close: Apr 25, 2024, 4:00 PM
21.31
-0.09 (-0.42%)
Pre-market: Apr 26, 2024, 5:11 AM EDT
Fusion Pharmaceuticals Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for FUSN stock have an average target of 20.86, with a low estimate of 15 and a high estimate of 24. The average target predicts a decrease of -2.52% from the current stock price of 21.40.
Analyst Consensus: Hold
* Price targets were last updated on Mar 21, 2024.
Analyst Ratings
The average analyst rating for FUSN stock from 12 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 2 | 2 | 2 | 0 | 0 |
| Buy | 5 | 4 | 4 | 4 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 10 | 11 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 11 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| TD Cowen | TD Cowen | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Apr 16, 2024 |
| RBC Capital | RBC Capital | Hold Reiterates $21 | Hold | Reiterates | $21 | -1.87% | Mar 21, 2024 |
| Wedbush | Wedbush | Hold Reiterates $24 | Hold | Reiterates | $24 | +12.15% | Mar 21, 2024 |
| RBC Capital | RBC Capital | Buy → Hold Downgrades $16 → $21 | Buy → Hold | Downgrades | $16 → $21 | -1.87% | Mar 20, 2024 |
| Raymond James | Raymond James | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Mar 20, 2024 |
Financial Forecast
Revenue This Year
528.36K
from 2.07M
Decreased by -74.45%
Revenue Next Year
591.43K
from 528.36K
Increased by 11.94%
EPS This Year
-1.45
from -1.45
EPS Next Year
-1.73
from -1.45
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 3.6M | 3.7M | 51.7M | 70.4M | 179.6M |
| Avg | 528,360 | 591,427 | 9.0M | 13.7M | 45.0M |
| Low | n/a | n/a | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 74.9% | 591.4% | 8,645.5% | 678.3% | 1,209.7% |
| Avg | -74.5% | 11.9% | 1,428.3% | 51.7% | 228.3% |
| Low | - | - | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.13 | -1.35 | -1.73 | -0.78 | -0.38 |
| Avg | -1.45 | -1.73 | -1.92 | -1.47 | -1.38 |
| Low | -1.74 | -1.98 | -2.03 | -2.10 | -2.29 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.